Urine Test for Cystic Fibrosis Patients is Beneficial: Study

A urine test in patients with cystic fibrosis could be beneficial, according to a new study. The urine test will help analyze the cystic fibrosis transmembrane conductance regulator in patients.

Urine test for patients with cystic fibrosis could be beneficial, according to a new study. The study also provides insights on the effects of cystic fibrosis in the kidneys.

The first hormone—called secretin —was discovered in 1902.

Simple Noninvasive Test can Help Personalize Cystic Fibrosis Treatment
Personalized medications can now be developed by a simple non invasive test for cystic fibrosis found a new study

‘Urine test in cystic fibrosis patients beneficial, according to a new study. A urine test will help identify the cystic fibrosis transmembrane conductance regulator (CFTR) in individual patients and offer novel treatment strategies.’
Read More..

Secretin stimulates the secretion of bicarbonate in the pancreas to neutralize acids. This requires a membrane protein and chloride channel called the cystic fibrosis transmembrane conductance regulator (CFTR), which is defective in patients suffering from cystic fibrosis, a condition that causes thick mucus to clog the lungs and obstruct the pancreas.

In patients with this disease, there is no increase in urinary excretion of bicarbonate following treatment with secretin.

A team led by Jens Leipziger, MD, PhD (Aarhus University) and Karl Kunzelmann, MD, PhD (University of Regensburg) studied several mouse models, patients with cystic fibrosis, and different types of cells to define the mechanisms involved in the urinary excretion of bicarbonate, and how these mechanisms are affected by cystic fibrosis.

Coughing Unable to Bring Out Mucus in Cystic Fibrosis: Here's Why
Scientists discover why it is difficult to bring out mucus from the airways in certain lung diseases such as cystic fibrosis and chronic bronchitis by means of coughing.

They also found that a urine test of bicarbonate may help to assess CFTR function in patients, which may be useful for assessing the potential of new medications.

“A simple urine test may become a useful tool to measure how much CFTR function is defective in each patient and also to see if novel treatment strategies have an effect,” said Dr. Leipziger.

FDA Approves Ivacaftor Drug for Cystic Fibrosis : More Patients to Benefit
The US FDA has allowed the use of ivacaftor for 23 additional mutations in cystic fibrosis patients, thereby allowing more patients to experience its benefits.

The study was published in JASN . Study co-authors include Peder Berg, Samuel L. Svendsen, Mads V. Sorensen, PhD, Casper K. Larsen, PhD, Jesper Frank Andersen, Soren Jensen-Fangel, MD, Majbritt Jeppesen, MD, PhD, Rainer Schreiber, and Ines Cabrita.

Cystic Fibrosis Patients With Specific Mutations To Benefit From New Drug
A new combination drug for cystic fibrosis has been approved by the USFDA in people ages 12 and older that can treat the underlying cause of the disease.

Source-Newswise